Novel Biomarkers in the U.S. for Management of Preeclampsia and Neuroendocrine Tumors

Wednesday, July 26
2:45 – 3:45 p.m.
Exhibit Hall Theater 1
Supported by Thermo Fisher Scientific


Learn from our two speakers about the new biomarkers PlGF, sFlt-1, and CgA for management of preeclampsia and neuroendocrine tumors. Preeclampsia is a life-threatening pregnancy complication affecting 8% of the pregnant women in the United States. PlGF and sFlt-1 can help to identify hospitalized women who will progress to a severe form of preeclampsia, thus improving clinical management of this condition. Chromogranin A (CgA) is a tumor marker recognized as gold standard in grade 1/2 neuroendocrine tumors. Although widely known, only LDTs – usually manual – are available in the United States. Currently, FDA 510K is pending for B·R·A·H·M·S CgAII KRYPTOR, the only fully automated CgA assay. 


Kai Staeding
Product Manager, Thermo Fisher Scientific


Anders Berg
Associate Professor, Pathology, Bioscience
Associate Director, Clinical Chemistry
Cedars Sinai